Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Samelisant"

4 News Found

Suven Life Sciences to showcase narcolepsy program Samelisant at SLEEP 2026
News | June 14, 2026

Suven Life Sciences to showcase narcolepsy program Samelisant at SLEEP 2026

Samelisant will be the centerpiece of Suven’s scientific presence


Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024
Clinical Trials | April 16, 2024

Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024

Global Phase-3 study initiation expected in the second half of 2024


Suven Life Sciences completes enrollment of patients to the phase-2, PoC clinical study of samelisant for the treatment of narcolepsy
News | June 02, 2023

Suven Life Sciences completes enrollment of patients to the phase-2, PoC clinical study of samelisant for the treatment of narcolepsy

Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada


Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant
News | October 05, 2024

Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant

The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025